MannKind files Afresa, downplays inhaled aspect of its insulin:
This article was originally published in Pharmaceutical Approvals Monthly
Almost a year and a half after Pfizer admitted commercial defeat for the first inhaled insulin, Exubera, last-drug-developer-standing MannKind has filed the NDA for its inhaled insulin Afresa. The March 16 announcement continues MannKind's practice of downplaying the inhaled aspects of its insulin, stating that "the feature that distinguishes Afresa from all other insulin products is not the route of administration - it is the pharmacokinetic profile." Although the other manufacturers working on inhaled insulins abandoned the projects, MannKind persevered, arguing that the efficacy offered by the quick action (peak insulin levels in 12-14 minutes, mimicking the release of mealtime insulin in healthy people) - not convenience - is the rationale for the product. The firm also recently announced its plan to buy the German plant that produced Pfizer's Exubera. Having both the regulatory filing accomplished and the manufacturing capability should give the biotech a leg up in partnering talks - which had been put on hold after a lung cancer signal was detected in Exubera post-market data (1"The Pink Sheet" DAILY, Nov. 10, 2008)
You may also be interested in...
Afresa Phase III studies are complete, though FDA wants bioequivalence trial to support new inhaler device.
Janet Woodcock has been a no-nonsense acting commissioner, but there’s plenty of drama in the nomination process as opposition and support for her to become permanent head of the US FDA continues to mount while the wait for President Biden’s nominee drags on.
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.